The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “SERPINB3 in fibrogenic chronic liver diseases and primary liver cancers”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2024 |
Gianmarco Villano, Patrizia Pontisso. Protease activated receptor 2 as a novel druggable target for the treatment of metabolic dysfunction-associated fatty liver disease and cancer, Frontiers in Immunology. 2024; 15: 1397441. https://doi.org/10.3389/fimmu.2024.1397441 |
|
2 |
2025 |
Adane Adugna, Gashaw Azanaw Amare, Mohammed Jemal. Current Advancements in Serum Protein Biomarkers for Hepatitis B Virus‐Associated Hepatocyte Remodeling and Hepatocellular Carcinoma, Immunity, Inflammation and Disease. 2025; 13: e70171. https://doi.org/10.1002/iid3.70171 |
|
3 |
2026 |
Farah Alhajjar, Ahmad Manadili, Hasan Alzoubi. Association of Serum SCC-Ag With Baseline Disease Extent in Oral and Laryngeal SCC: Exploratory Cross-Sectional Study, International Dental Journal. 2026; 76: 111246111246. https://doi.org/10.1016/j.identj.2026.111246 |
|
4 |
2024 |
Silvia Cagnin, Patrizia Pontisso, Andrea Martini. SerpinB3: A Multifaceted Player in Health and Disease—Review and Future Perspectives, Cancers. 2024; 16: 2579. https://doi.org/10.3390/cancers16142579 |
|
5 |
2026 |
Monica Chinellato, Elisa Franzin, Filippo Vascon, Paul-Albert Koenig, Florian I. Schmidt, Patrizia Pontisso, Laura Cendron. A Picomolar MBP-Binding Nanobody for Target Enrichment and Modular Complex Engineering, ACS Bio & Med Chem Au. 2026; 6: 323. https://doi.org/10.1021/acsbiomedchemau.6c00053 |